Survival and Operative Outcomes After Salvage Surgery for Recurrent or Persistent Anal Cancer
- PMID: 33486907
- PMCID: PMC7837391
- DOI: 10.3393/ac.2020.12.29
Survival and Operative Outcomes After Salvage Surgery for Recurrent or Persistent Anal Cancer
Abstract
Anal squamous cell carcinoma (SCC) is a relatively rare cancer comprising less than 2.5% of all gastrointestinal malignancies. The standard treatment for anal SCC is primary chemoradiation therapy which can result in complete regression. After successful treatment, the 5-year survival is approximately 80%. However, up to 30% of patients experience recurrent persistent or recurrent disease. The role of surgery in the treatment of anal cancer, therefore, is limited to the management of recurrent or persistent disease with abdominoperineal resection and/or en bloc adjacent organ excision. Salvage surgery after irradiated anal cancer can be technically demanding in terms of acquisition of oncologically safe surgical margins and minimization of postoperative morbidity. In addition, 5-year survival outcomes after salvage resection have been reported to vary from 23% to 69%. Positive resection margins are generally regarded as the important risk factor associated with poor survival outcome. Perineal wound complications are the most common major postoperative morbidity. Because of the challenges of primary wound closure after salvage abdominoperineal resection, myocutaneous flap reconstruction has been performed to reduce the severity of perianal would complications. We, therefore, descriptively reviewed contemporary published evidence describing the treatment and outcomes after salvage surgery for persistent or recurrent anal SCC.
Keywords: Anal cancer; Persistent; Recurrent; Salvage; Squamous cell.
Conflict of interest statement
No potential conflict of interest relevant to this article was reported.
Figures


Similar articles
-
Oncologic Outcomes of Salvage Abdominoperineal Resection for Anal Squamous Cell Carcinoma Initially Managed with Chemoradiation.J Clin Med. 2024 Apr 9;13(8):2156. doi: 10.3390/jcm13082156. J Clin Med. 2024. PMID: 38673429 Free PMC article.
-
Abdominoperineal resection and perineal wound healing in recurrent, persistent, or primary anal carcinoma.Int J Colorectal Dis. 2016 Jun;31(6):1197-203. doi: 10.1007/s00384-016-2575-9. Epub 2016 Mar 31. Int J Colorectal Dis. 2016. PMID: 27033699
-
Salvage Abdominoperineal Resection for Anal Squamous Cell Carcinoma: Use, Risk Factors, and Outcomes in a Canadian Population.Dis Colon Rectum. 2020 Jun;63(6):748-757. doi: 10.1097/DCR.0000000000001630. Dis Colon Rectum. 2020. PMID: 32384405
-
A systematic review of outcomes after salvage abdominoperineal resection for persistent or recurrent anal squamous cell cancer.Colorectal Dis. 2019 Jun;21(6):632-650. doi: 10.1111/codi.14569. Epub 2019 Mar 22. Colorectal Dis. 2019. PMID: 30689272
-
So Now My Patient Has Squamous Cell Cancer: Diagnosis, Staging, and Treatment of Squamous Cell Carcinoma of the Anal Canal and Anal Margin.Clin Colon Rectal Surg. 2018 Nov;31(6):353-360. doi: 10.1055/s-0038-1668105. Epub 2018 Nov 2. Clin Colon Rectal Surg. 2018. PMID: 30397394 Free PMC article. Review.
Cited by
-
[Anal cancer-Interaction between outpatient and inpatient treatment].Chirurgie (Heidelb). 2025 Jun 27. doi: 10.1007/s00104-025-02337-5. Online ahead of print. Chirurgie (Heidelb). 2025. PMID: 40579585 Review. German.
-
Prognostic Value of Fusobacterium nucleatum after Abdominoperineal Resection for Anal Squamous Cell Carcinoma.Cancers (Basel). 2022 Mar 22;14(7):1606. doi: 10.3390/cancers14071606. Cancers (Basel). 2022. PMID: 35406380 Free PMC article.
-
Anal carcinoma - exploring the epidemiology, risk factors, pathophysiology, diagnosis, and treatment.World J Exp Med. 2024 Sep 20;14(3):98525. doi: 10.5493/wjem.v14.i3.98525. eCollection 2024 Sep 20. World J Exp Med. 2024. PMID: 39312693 Free PMC article. Review.
-
Follow-up imaging of anal cancer after treatment.Abdom Radiol (NY). 2023 Sep;48(9):2888-2897. doi: 10.1007/s00261-023-03895-0. Epub 2023 Apr 6. Abdom Radiol (NY). 2023. PMID: 37024606 Review.
-
Oncologic Outcomes of Salvage Abdominoperineal Resection for Anal Squamous Cell Carcinoma Initially Managed with Chemoradiation.J Clin Med. 2024 Apr 9;13(8):2156. doi: 10.3390/jcm13082156. J Clin Med. 2024. PMID: 38673429 Free PMC article.
References
-
- Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424. - PubMed
-
- Ajani JA, Winter KA, Gunderson LL, Pedersen J, Benson AB, 3rd, Thomas CR, Jr, et al. Fluorouracil, mitomycin, and radiotherapy vs fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal: a randomized controlled trial. JAMA. 2008;299:1914–21. - PubMed
-
- Lim F, Glynne-Jones R. Chemotherapy/chemoradiation in anal cancer: a systematic review. Cancer Treat Rev. 2011;37:520–32. - PubMed
-
- Welton ML, Sharkey FE, Kahlenberg MS. The etiology and epidemiology of anal cancer. Surg Oncol Clin N Am. 2004;13:263–75. - PubMed
-
- Roohipour R, Patil S, Goodman KA, Minsky BD, Wong WD, Guillem JG, et al. Squamous-cell carcinoma of the anal canal: predictors of treatment outcome. Dis Colon Rectum. 2008;51:147–53. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Research Materials